N-[2-[3-(4-ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-2-[4-fluoro-3-(trifluoromethyl)phenyl]-N-(pyridin-3-ylmethyl)acetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[2-[3-(4-ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-2-[4-fluoro-3-(trifluoromethyl)phenyl]-N-(pyridin-3-ylmethyl)acetamide
• 化学式: C₃₂H₂₇F₄N₅O₃
• 分子量: 605.6
• InChiKey: DEBDZYGKCQRLCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  44
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  88
• 氢给体数：
  0
• 氢受体数：
  10

文献信息

• METHODS FOR DIAGNOSING, SCREENING, IDENTIFYING, MONITORING, AND TREATING ADVERSE LOCAL TISSUE REACTIONS, WHICH LEAD TO FAILURE OF ORTHOPEDIC IMPLANTS
  申请人：NEW YORK SOCIETY FOR THE RUPTURED AND CRIPPLED MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY

  公开号：US20160281165A1

  公开（公告）日：2016-09-29

  This invention relates to field of screening and diagnosing adverse local tissue reactions or ALTR using proteins and genes that are elevated in patients suffering from ALTR, even those with no symptoms. The early diagnosis of the ALTR can lead to its treatment and thus, the prevention of implant failure caused by the ALTR. The elevated proteins and genes are also the basis for treatment for ALTR and provide targets for drug development and basic research.
• USE OF CXCR3 INHIBITORS FOR PROTECTING AGAINST FETAL WASTAGE
  申请人：Children's Hospital Medical Center

  公开号：US20180022810A1

  公开（公告）日：2018-01-25

  Provided herein are compositions and methods related to reducing the risk of or preventing fetal wastage in a subject using a CXCR3 inhibitor.